pioglitazone has been researched along with Breast Cancer in 19 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this research, we evaluated the anti-invasive property of pioglitazone along with antitumor effects of doxorubicin on MDA-MB-231 breast cancer cell lines." | 8.12 | Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells. ( Amini, A; Boshagh, MA; Malakouti, P; Mohammadi, M; Rahmani, MR; Rezaee, MA, 2022) |
| "Whether pioglitazone may affect breast cancer risk in female diabetes patients is not conclusive and has not been investigated in the Asian populations." | 8.12 | Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. ( Tseng, CH, 2022) |
| "Therefore, the expression of PPARγ in breast cancer was analyzed by online software UALCAN whose data were from the TCGA database." | 5.56 | The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway. ( Chen, ZH; Deng, L; Hu, GH; Jiang, Y; Jiao, XX; Li, ZH; Lian, SX; Lin, SY; Lu, WQ; Qiu, YR; Zhang, Y, 2020) |
| "In this research, we evaluated the anti-invasive property of pioglitazone along with antitumor effects of doxorubicin on MDA-MB-231 breast cancer cell lines." | 4.12 | Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells. ( Amini, A; Boshagh, MA; Malakouti, P; Mohammadi, M; Rahmani, MR; Rezaee, MA, 2022) |
| "Whether pioglitazone may affect breast cancer risk in female diabetes patients is not conclusive and has not been investigated in the Asian populations." | 4.12 | Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. ( Tseng, CH, 2022) |
| "Therefore, the expression of PPARγ in breast cancer was analyzed by online software UALCAN whose data were from the TCGA database." | 1.56 | The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway. ( Chen, ZH; Deng, L; Hu, GH; Jiang, Y; Jiao, XX; Li, ZH; Lian, SX; Lin, SY; Lu, WQ; Qiu, YR; Zhang, Y, 2020) |
| "Furthermore, treating breast cancer cells with pioglitazone that stabilizes the 3Cys-1His cluster of NAF-1 results in a similar effect on mitochondrial iron and reactive oxygen species accumulation." | 1.43 | Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters. ( Bai, F; Darash-Yahana, M; Geiger, T; Jennings, PA; Karmi, O; Lu, M; Mittler, R; Nechushtai, R; Onuchic, JN; Pikarsky, E; Pozniak, Y; Sohn, YS; Song, L; Tamir, S, 2016) |
| " However, since the inhibition of transporter is not specific to cancer cells, a decrease in the cytotoxic drug dosing may be needed to prevent excess toxicity, thus undermining the potential benefit brought about by a drug efflux inhibitor." | 1.39 | Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists. ( To, KK; Tomlinson, B, 2013) |
| "Here, we expanded MSs from human breast cancer and normal mammary gland tissues, as well from tumorigenic (MCF7) and non-tumorigenic (MCF10) breast cell lines." | 1.38 | Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. ( Avenia, N; Bonafé, M; Ceccarelli, C; De Carolis, S; Guarnieri, T; Orlandi, M; Papi, A; Sanguinetti, A; Santini, D; Sidoni, A; Storci, G; Taffurelli, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Metwally, K | 1 |
| Pratsinis, H | 1 |
| Kletsas, D | 1 |
| Malakouti, P | 1 |
| Mohammadi, M | 1 |
| Boshagh, MA | 1 |
| Amini, A | 1 |
| Rezaee, MA | 1 |
| Rahmani, MR | 1 |
| Tseng, CH | 1 |
| Zhou, J | 1 |
| Liu, Z | 1 |
| Zhang, L | 1 |
| Hu, X | 1 |
| Wang, Z | 1 |
| Ni, H | 1 |
| Wang, Y | 1 |
| Qin, J | 1 |
| Kalra, S | 1 |
| Priya, G | 1 |
| Bhattacharya, S | 1 |
| Sahay, R | 1 |
| Jiao, XX | 1 |
| Lin, SY | 1 |
| Lian, SX | 1 |
| Qiu, YR | 1 |
| Li, ZH | 1 |
| Chen, ZH | 1 |
| Lu, WQ | 1 |
| Zhang, Y | 1 |
| Deng, L | 1 |
| Jiang, Y | 1 |
| Hu, GH | 1 |
| Sohn, YS | 2 |
| Tamir, S | 2 |
| Song, L | 2 |
| Michaeli, D | 1 |
| Matouk, I | 1 |
| Conlan, AR | 1 |
| Harir, Y | 1 |
| Holt, SH | 1 |
| Shulaev, V | 1 |
| Paddock, ML | 1 |
| Hochberg, A | 1 |
| Cabanchick, IZ | 1 |
| Onuchic, JN | 2 |
| Jennings, PA | 2 |
| Nechushtai, R | 2 |
| Mittler, R | 2 |
| To, KK | 1 |
| Tomlinson, B | 1 |
| Papi, A | 2 |
| De Carolis, S | 2 |
| Bertoni, S | 1 |
| Storci, G | 2 |
| Sceberras, V | 1 |
| Santini, D | 2 |
| Ceccarelli, C | 2 |
| Taffurelli, M | 2 |
| Orlandi, M | 2 |
| Bonafé, M | 2 |
| Kole, L | 1 |
| Sarkar, M | 1 |
| Deb, A | 1 |
| Giri, B | 1 |
| Darash-Yahana, M | 1 |
| Pozniak, Y | 1 |
| Lu, M | 1 |
| Karmi, O | 1 |
| Bai, F | 1 |
| Pikarsky, E | 1 |
| Geiger, T | 1 |
| Nicolau Ramis, J | 1 |
| Masmiquel Comas, L | 1 |
| Guarnieri, T | 1 |
| Avenia, N | 1 |
| Sanguinetti, A | 1 |
| Sidoni, A | 1 |
| Khoo, BY | 1 |
| Miswan, N | 1 |
| Balaram, P | 1 |
| Nadarajan, K | 1 |
| Elstner, E | 2 |
| Subbaramaiah, K | 1 |
| Howe, LR | 1 |
| Zhou, XK | 1 |
| Yang, P | 1 |
| Hudis, CA | 1 |
| Kopelovich, L | 1 |
| Dannenberg, AJ | 1 |
| Margalit, O | 1 |
| Wang, D | 1 |
| Dubois, RN | 1 |
| Ece, H | 1 |
| Cigdem, E | 1 |
| Yuksel, K | 1 |
| Ahmet, D | 1 |
| Hakan, E | 1 |
| Oktay, TM | 1 |
| Liu, H | 1 |
| Zang, C | 1 |
| Fenner, MH | 1 |
| Possinger, K | 1 |
| Ge, H | 1 |
| Zhang, JF | 1 |
| Guo, BS | 1 |
| He, B | 1 |
| Wang, BY | 1 |
| Wang, CQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy[NCT02882477] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Breast Cancer
| Article | Year |
|---|---|
Oncocrinology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Endocri | 2020 |
18 other studies available for pioglitazone and Breast Cancer
| Article | Year |
|---|---|
Novel 2,4- thiazolidinediones: Synthesis, in vitro cytotoxic activity, and mechanistic investigation.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Fem | 2017 |
Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Pioglitazone | 2022 |
Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Topics: Breast Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; In | 2022 |
Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Lung | 2020 |
The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cell Survival; Female; Humans; Janus Kinase 2; Mice; | 2020 |
NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.
Topics: Animals; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fema | 2013 |
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2013 |
PPARγ and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche.
Topics: Antigens, Neoplasm; Apolipoproteins E; Biomarkers, Tumor; Breast Neoplasms; Carbonic Anhydrase IX; C | 2014 |
Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; E | 2016 |
Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; | 2016 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; | 2012 |
Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Inflammation; Interleukin-6; Neop | 2012 |
Modification of MCF-10A cells with pioglitazone and serum-rich growth medium increases soluble factors in the conditioned medium, likely reducing BT-474 cell growth.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation | 2012 |
Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.
Topics: Adipose Tissue; Animals; Aromatase; Blotting, Western; BRCA1 Protein; Breast Neoplasms; Cells, Cultu | 2012 |
PPARγ agonists target aromatase via both PGE2 and BRCA1.
Topics: Aromatase; BRCA1 Protein; Breast Neoplasms; Dinoprostone; Female; Humans; Hydroxyprostaglandin Dehyd | 2012 |
Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Blood Glucose; Breast Neoplasms; Case-Control Stu | 2012 |
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro.
Topics: Breast Neoplasms; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiven | 2003 |
[Resveratrol inhibits expression of EMMPRIN from macrophages].
Topics: Anilides; Antineoplastic Agents, Phytogenic; Basigin; Blotting, Western; Breast Neoplasms; Cell Diff | 2006 |